Granted Patent
B2
US 12,371,747 · App. 17/681,435 · Granted Jul 29, 2025
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
Inventors:
Haiyan Jiang (Belmont, MA); Tongyao Liu (Lexington, MA); Sriram Krishnamoorthy (Medford, MA); Neil Josephson (Seattle, WA); Glenn Pierce (Cambridge, MA)
C12Q1/6883A61K38/21A61K38/37A61K39/0008A61K47/6811A61K47/6815C07K14/755A61K2039/6031A61K2039/6056C07K2319/30C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
Claims (25)
1. A method of reducing an inhibitory Factor VIII (FVIII) immune response in a subject who has hemophilia A, comprising administering to the subject a chimeric polypeptide comprising a FVIII polypeptide and an Fc, wherein the Fc comprises an amino acid sequence at least 95% identical to amino acids 1458 to 1684 of SEQ ID NO: 2, wherein the subject has developed an inhibitory FVIII immune response to a FVIII protein, and wherein the immune response comprises inhibitory anti-FVIII antibodies, wherein the subject is identified to have one or more characteristics selected from the group consisting of:
(a) is receiving interferon therapy;
(b) is receiving anti-viral therapy;
(c) has a genetic mutation in a gene other than the gene encoding FVIII which is linked with an increased risk of developing an inhibitory immune response; and
(d) any combination thereof.
2. The method of claim 1 , wherein the subject has a relative who has previously developed an inhibitory FVIII immune response.
3. The method of claim 1 , wherein the FVIII polypeptide comprises an amino acid sequence at least 90% identical to amino acids 20 to 1457 of SEQ ID NO: 2.
4. The method of claim 1 , further comprising measuring the level of the inhibitory FVIII immune response before the administration of the chimeric polypeptide.
5. The method of claim 4 , further comprising comparing the level of the inhibitory FVIII immune response after the administration of the chimeric polypeptide with the level of the inhibitory FVIII immune response before the administration of the chimeric polypeptide.
6. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies prior to the administration of the chimeric polypeptide is at least about 0.6 Bethesda Units (BU).
7. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies prior to the administration of the chimeric polypeptide is at least about 1.0 BU.
8. The method of claim 1 , wherein the concentration of the inhibitory antibodies prior to the administration is at least about 5.0 Bethesda Units (BU).
9. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies after the administration of the chimeric polypeptide is less than about 1.0 BU.
10. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies after the administration of the chimeric polypeptide is less than about 0.6 BU.
11. The method of claim 1 , wherein the subject has one or more of:
(i) a genetic polymorphism associated with increased TNF-α;
(ii) a genetic polymorphism associated with increased IL-10;
(iii) a genetic polymorphism associated with decreased CTLA-4; and
(iv) a mutation in DR15 or DQB0602 MHC Class II molecules.
12. The method of claim 1 , wherein the chimeric polypeptide comprises a linker between the FVIII polypeptide and the Fc.
13. The method of claim 1 , wherein the chimeric polypeptide comprises an amino acid sequence identical to amino acids 1458 to 1683 of SEQ ID NO: 2.
14. The method of claim 1 , wherein the FVIII polypeptide comprises an amino acid sequence identical to amino acids 20 to 1457 of SEQ ID NO: 2.
15. The method of claim 1 , wherein the chimeric polypeptide is in the form of a hybrid comprising a second polypeptide associated with the chimeric polypeptide via a disulfide bond, wherein the second polypeptide comprises a second Fc portion, and wherein the second Fc portion comprises an amino acid sequence at least 95% identical to amino acids 21 to 247 of SEQ ID NO: 4.
16. The method of claim 1 , wherein the subject is a child less than twelve years old.
17. The method of claim 1 , wherein the subject is an adult.
Assignments (4)
CHANGE OF NAME
Recorded Feb 28, 2022
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 059511/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 28, 2022
From: BIOGEN MA INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 059511/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 28, 2022
From: JIANG, HAIYAN; LIU, TONGYAO; KRISHNAMOORTHY, SRIRAM; PIERCE, GLENN
To: BIOGEN IDEC MA INC.
Reel/Frame 059114/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 28, 2022
From: JOSEPHSON, NEIL
To: PUGET SOUND BLOOD CENTER
Reel/Frame 059114/0831 →
Continuity (5)
Continuation
14371931
Provisional Application
61586103
· Jan 12, 2012
Provisional Application
61668961
· Jul 6, 2012
References Cited (314)
US 4695199A
· Capon et al.
· 1987
[cited by applicant]
US 4757006A
· Toole et al.
· 1988
[cited by applicant]
US 4868112A
· Toole et al.
· 1989
[cited by applicant]
US 4994371A
· Davie et al.
· 1991
[cited by applicant]
US 5004803A
· Kaufman et al.
· 1991
[cited by applicant]
US 5112950A
· Meulien et al.
· 1992
[cited by applicant]
US 5171844A
· van Ooyen et al.
· 1992
[cited by applicant]
US 5364771A
· Lollar et al.
· 1994
[cited by applicant]
US 5543502A
· Nordfang et al.
· 1996
[cited by applicant]
US 5595886A
· Chapman et al.
· 1997
[cited by applicant]
US 5610278A
· Nordfang et al.
· 1997
[cited by applicant]
US 5789203A
· Chapman et al.
· 1998
[cited by applicant]
US 5859204A
· Lollar et al.
· 1999
[cited by applicant]
US 5972885A
· Spira et al.
· 1999
[cited by applicant]
US 6048720A
· Dalborg et al.
· 2000
[cited by applicant]
US 6060447A
· Chapman et al.
· 2000
[cited by applicant]
US 6228620B1
· Chapman et al.
· 2001
[cited by applicant]
US 6251632B1
· Lillicrap et al.
· 2001
[cited by applicant]
US 6316226B1
· Van Ooyen et al.
· 2001
[cited by applicant]
US 6346513B1
· Van Ooyen et al.
· 2002
[cited by applicant]
US 6376463B1
· Lollar et al.
· 2002
[cited by applicant]
US 6458563B1
· Lollar et al.
· 2002
[cited by applicant]
US 7041635B2
· Kim et al.
· 2006
[cited by applicant]
US 7348004B2
· Peters
· 2008
[cited by examiner]
US 7381408B2
· Mezo et al.
· 2008
[cited by applicant]
US 7404956B2
· Peters et al.
· 2008
[cited by applicant]
US 7820162B2
· Mezo et al.
· 2010
[cited by applicant]
US 7862820B2
· Peters et al.
· 2011
[cited by applicant]
US 8329182B2
· Peters et al.
· 2012
[cited by applicant]
US 8759293B2
· Barnett
· 2014
[cited by applicant]
US 8815250B2
· Rivera
· 2014
[cited by examiner]
US 8932830B2
· Peters et al.
· 2015
[cited by applicant]
US 9050318B2
· Dumont
· 2015
[cited by examiner]
US 9233145B2
· Pierce
· 2016
[cited by examiner]
US 9241978B2
· Dumont
· 2016
[cited by examiner]
US 9266145B2
· Maurer et al.
· 2016
[cited by applicant]
US 9623091B2
· Pierce
· 2017
[cited by examiner]
US 9629903B2
· Pierce
· 2017
[cited by examiner]
US 9636416B2
· Peters et al.
· 2017
[cited by applicant]
US 9670475B2
· Pierce
· 2017
[cited by examiner]
US 9675676B2
· Pierce
· 2017
[cited by examiner]
US 9867873B2
· Pierce
· 2018
[cited by examiner]
US 20020038002A1
· Zaghouani et al.
· 2002
[cited by applicant]
US 20030211113A1
· Kakkis et al.
· 2003
[cited by applicant]
US 20040096456A1
· Conti-fine
· 2004
[cited by examiner]
US 20040110929A1
· Bjorn et al.
· 2004
[cited by applicant]
US 20050100990A1
· Saenko et al.
· 2005
[cited by applicant]
US 20050147618A1
· Rivera et al.
· 2005
[cited by applicant]
US 20050260194A1
· Peters et al.
· 2005
[cited by applicant]
US 20090163699A1
· Chamberlain et al.
· 2009
[cited by applicant]
US 20090264627A1
· Gillies et al.
· 2009
[cited by applicant]
US 20110159540A1
· Mezo et al.
· 2011
[cited by applicant]
US 20110182896A1
· Rivera et al.
· 2011
[cited by applicant]
US 20110268737A1
· Favier et al.
· 2011
[cited by applicant]
US 20120142593A1
· Zhao et al.
· 2012
[cited by applicant]
US 20130108629A1
· Dumont et al.
· 2013
[cited by applicant]
US 20130171175A1
· Pierce et al.
· 2013
[cited by applicant]
US 20130202595A1
· Pierce et al.
· 2013
[cited by applicant]
US 20130274194A1
· Dumont et al.
· 2013
[cited by applicant]
US 20150252345A1
· Pierce et al.
· 2015
[cited by applicant]
US 20150266944A1
· Jiang et al.
· 2015
[cited by applicant]
US 20160199455A1
· Dumont et al.
· 2016
[cited by applicant]
US 20160257943A1
· Pierce et al.
· 2016
[cited by applicant]
US 20160346365A1
· Pierce et al.
· 2016
[cited by applicant]
US 20170226189A1
· Peters et al.
· 2017
[cited by applicant]
CA 2863329A1
· 2013
[cited by applicant]
EP 0295597A2
· 1988
[cited by applicant]
EP 2184070A1
· 2010
[cited by applicant]
EP 2802668A1
· 2014
[cited by applicant]
EP 3453402A1
· 2019
[cited by applicant]
JP 2005530762A
· 2005
[cited by applicant]
JP 2007500744A
· 2007
[cited by applicant]
JP 2011505414A
· 2011
[cited by applicant]
JP 2011523663A
· 2011
[cited by applicant]
JP 2012507994A
· 2012
[cited by applicant]
JP 2012522490A
· 2012
[cited by applicant]
JP 2013510581A
· 2013
[cited by applicant]
JP 2013512678A
· 2013
[cited by applicant]
JP 2017149784A
· 2017
[cited by applicant]
WO WO1987004187A1
· 1987
[cited by applicant]
WO WO1988000831A1
· 1988
[cited by applicant]
WO WO1988003558A1
· 1988
[cited by applicant]
WO WO1988008035A1
· 1988
[cited by applicant]
WO WO1991009122A1
· 1991
[cited by applicant]
WO WO1993020093A1
· 1993
[cited by applicant]
WO WO1994011503A2
· 1994
[cited by applicant]
WO WO2004101739A2
· 2004
[cited by applicant]
WO WO2004101740A2
· 2004
[cited by applicant]
WO WO2005001025A2
· 2005
[cited by applicant]
WO WO2006074199A1
· 2006
[cited by applicant]
WO WO200914930A1
· 2009
[cited by applicant]
WO WO2009071886A1
· 2009
[cited by applicant]
WO WO2009149303A1
· 2009
[cited by applicant]
WO WO2010006635A1
· 2010
[cited by applicant]
WO WO2010052228A1
· 2010
[cited by applicant]
WO WO2010111414A1
· 2010
[cited by applicant]
WO WO2011060242A2
· 2011
[cited by applicant]
WO WO2011069164A2
· 2011
[cited by examiner]
WO WO2012006623A2
· 2012
[cited by applicant]
WO WO2013106789A1
· 2013
[cited by applicant]
Astermark, J. Haemophilia. Dec. 2006;12 Suppl 6:8-13; discussion 13-4.
[cited by examiner]
George et al., J Blood Med. Apr. 24, 2015;6:131-41. doi: 10.2147/JBM.S54632. eCollection 2015.
[cited by examiner]
Kreuz et al., Haemophilia. Jan. 1995;1(1):24-32. doi: 10.1111/j.1365-2516.1995.tb00036.x.
[cited by examiner]
Mariani et al., Semin Thromb Hemost. Feb. 2003;29(1):69-76.
[cited by examiner]
Astermark et al., Haemophilia. May 2001;7(3):267-72. doi: 10.1046/j.1365-2516.2001.00510.x. PMID: 11380630.
[cited by examiner]
Akilesh, S., et al., “Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism” The Journal of Immunology 179(7):4580-4588, The American Association of Immunologists, Inc., Uni…
[cited by applicant]
Aledort, L.M., et al., “A longitudinal study of orthopaedic outcomes for severe factor-VIII deficient haemophiliacs,” Journal of Internal Medicine 236(4):391-399, Blackwell Scientific Publications, England (1994).
[cited by applicant]
Armour, K.L., et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,” European Journal of Immunology 29(8):2613-2624, Wiley-VCH Verlag GmbH, Germany (1999).
[cited by applicant]
Astermark et al., (2005) “The Malmö International Brother Study (MIBS): Genetic defects and inhibitor development in siblings with severe hemophilia A”, Haematologica, 90(7): 924-931.
[cited by applicant]
Astermark, et al., “Basic Aspects of Inhibitors to Factors VIII and IX and the Influence of Non-Genetic Risk Factors”, J. Haemophilia, vol. 12, Supplement 6, pp. 8-13, Dec. 2006.
[cited by applicant]
Astermark, J., et al., “Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A,” Journal of Thrombosis and Haemostasis 5(2):263-265, International Society on Thrombosis and Haemo…
[cited by applicant]
Astermark, J., et al., “Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A,” Blood 107(8):3167-3172, The American Society of Hematology…
[cited by applicant]
Astermark, J., et al., “Polymorphisms in the TNF a Gene and the Risk of Inhibitor Development in Patients with Hemophilia A,” Blood 108(12):3739-3745, The American Society of Hematology, United States (2006).
[cited by applicant]
Aznar, J.A., et al., “The orthopaedic status of severe haemophiliacs in Spain,” Haemophilia 6(3):170-176, Blackwell Science, England (2000).
[cited by applicant]
Bajaj, S.P., et al., “Redetermination of the Rate-Limiting Step in the Activation of Factor IX by Factor Xla and by Factor VIIa/Tissue Factor. Explanation for Different Electrophoretic Radioactivity Profiles Obtained on…
[cited by applicant]
Bi, L., et al., “Targeted Disruption of the Mouse Factor VIII Gene Produces a Model of Haemophilia A,” Nature Genetics 10(1):119-121, Nature Publishing Co., United States (1995).
[cited by applicant]
Bitonti, A.J., et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway,” Proceedings of the National Academy of Sciences USA 101(26):9763-9768…
[cited by applicant]
Borvak, J., et al., “Functional Expression of the MHC Class I-related Receptor, FcRn, in Endothelial Cells of Mice,” International Immunology 10(9):1289-1298, Oxford University Press, i England (1998).
[cited by applicant]
Brandstetter, H., et al., “X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B,” Proceedings of the National Academy of Sciences USA 92(21):9796-9800, The N…
[cited by applicant]
Brunetti-Pierri, N., et al., “Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B,” Human Gene Therapy 20(5):479-485, Mary Ann Liebe…
[cited by applicant]
Brutlag, D.L., et al., “Improved sensitivity of biological sequence database searches,” Computer Applications in the Biosciences 6(3):237-245, Oxford University Press, England (1990).
[cited by applicant]
Burmeister, W.P., et al., “Crystal structure of the complex of rat neonatal Fc receptor with Fc,” Nature 372(6504):379-383, Nature Publishing Group, England (1994).
[cited by applicant]
Butenas, S. and Mann, K.G., “Blood coagulation,” Biochemistry (Moscow) 67(1):3-12, MAIK Nauka/Interperiodica, United States (2002).
[cited by applicant]
Cameron, C., et al., “The canine factor VIII cDNA and 5′ flanking sequence,” Thrombosis and Haemostasis 79(2):317-322, Schattauer Verlag, Germany (1998).
[cited by applicant]
Cao, O., et al., “Role of regulatory T cells in tolerance to coagulation factors,” Journal of Thrombosis and Haemostasis 7(Suppl 1):88-91, Blackwell Publishing, England (2009).
[cited by applicant]
Castaman, G., et al., “Pregnancy and Delivery in Women with Von Willebrand's Disease and Different Von Willebrand Factor Mutations,” Haematologica 95(6):963- 969, Ferrata Storti Foundation, Italy (2010).
[cited by applicant]
Chang, J., et al., “Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity,” The Journal of Biological Chemistry 273(20):12089-12094, The American Society for Biochemis…
[cited by applicant]
Coppola et al., (2009) “Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors”, J Thromb Haemost, 7(11): 1809-1815, doi:10.1111/j…
[cited by applicant]
Coppola, A., et al., “Primary Prophylaxis in Children with Haemophilia,” Blood Transfusion Prophylaxis in Congenital Coagulation Disorders 6(Suppl 2):s4-s11, Society of Transfusion Medicine and Immunohaematology, Italy …
[cited by applicant]
Cutler, J.A., et al., “The identification and classification of 41 novel mutations in the factor VIII gene (F8C),” Human Mutation 19(3):274-278, Wiley Liss, Inc., United States (2002).
[cited by applicant]
Damiano et al., (2000) “Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience”, The Tri-Regional Nursing Group, Haemophilia, 6(5): 526-532.
[cited by applicant]
De Groot, A.S., et al., “Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”,” Blood 112(8):3303-331 I, The American Society of Hematology, United States (2008).
[cited by applicant]
De Groot, et al., “Activation of Natural Regulatory T Cells by IgG Fc-Derived Peptide ‘Tregitopes’”, Blood, vol. 112, No. 8, pp. 3303-3311, Oct. 15, 2008.
[cited by applicant]
Delignant, “Transplacental Delivery of FC-Fused Recombinant Factor VIII (
[cited by applicant]
Delignant, Abstract—“Transplacental Delivery of FC-Fused Factor VIII (
[cited by applicant]
Dimichele et al., (2002) “The North American Immune Tolerance Registry: practices, outcomes, outcome predictors”, Thromb Haemost, 87(1): 52-57.
[cited by applicant]
Dimichele, (2009) “The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy”, Haemophilia, 15(1): 320-328, doi:10.1111/j.1365-2516.2008.01880.x.
[cited by applicant]
Dobeli, H., et al., “Role of the carboxy-terminal sequence on the biological activity of human immune interferon (IFN-γ),” Journal of Biotechnology 7:199-216, Elsevier Science Publishers B.V., Netherlands (1998).
[cited by applicant]
Dumont, J.A., et al., “Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway,” Journal of Aerosol Medicine 18(3):294-303, May Ann Liebert, Inc., United State…
[cited by applicant]
Dumont, J.A., et al., “Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs,” ASH 51st Annual Meeting Abstracts 114(22): Abstract 545, The American Society of Hematology, U…
[cited by applicant]
Dumont, J.A., et al., “Monomeric Fc Fusion Technology: An Approach to Create Long-Lasting Clotting Factors,” in: Therapeutic Proteins—Strategies to Modulate Half-Life, Kontermann R., ed., Chapter 10, pp. 189-206, Wiley …
[cited by applicant]
Dumont, J.A., et al., “Monomeric Fc Fusion: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics,” BioDrugs 20(3):151-160, Adis Data Information B.V., New Zealand (2006).
[cited by applicant]
Dumont, J.A., et al., “Prolonged Activity of a Recombinant Factor VIII-Fc Fusion Protein in Hemophilia a Mice and Dogs,” Blood 119(13):3024-3030, The American Society of Hematology, United States (Mar. 29, 2012).
[cited by applicant]
Eaton, D.L., et al., “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule,” Biochemistry 25(26):8343-8347, The American Chemical Society, United States (1986).
[cited by applicant]
Eckhardt, C.L., et al., “Surgery and inhibitor development in hemophilia A: a systematic review,” Journal of Thrombosis and Haemostasis 9(10):1948-1958, Blackwell Publishing, England (Oct. 2011).
[cited by applicant]
Eigenbrot, et al., “The Factor VII Zymogen Structure Reveals Reregistration of β Strands during Activation”, Structure, vol. 9, No. 7, pp. 627-636, Jul. 3, 2001.
[cited by applicant]
English language Abstract of European Patent Publication No. EP 0295597 A2, European Patent Office, Espacenet database—Worldwide (1988).
[cited by applicant]
Extended European Search Report for European Application No. 18183272.6, dated Feb. 13, 2019.
[cited by applicant]
Fatouros, A., et al., “Recombinant factor VIII SQ influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution,” International Journal of Pharmaceutics 155(1):121-131, Elsevier, United Sta…
[cited by applicant]
Feagan, et al., “Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease”, New England Journal of Medicine, vol. 375, No. 20, pp. 1946-1960, Nov. 17, 2016.
[cited by applicant]
Feldman, B.M., et al., “Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study,” Journal of Thrombosis and Haemostasis 4(6):1228-1236, Bl…
[cited by applicant]
Foster, P.A., et al., “Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine,” Blood 75(10):1999-2004, The American Soci…
[cited by applicant]
Franchini et al., (2011), “Immune tolerance induction for patients with severe hemophilia A: a critical literature review”, J Thromb Thrombolysis, 32(4): 439-447, doi:10.1007/s11239-011-0624-3.
[cited by applicant]
Franchini et al., (2013) “Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update”, Semin Thromb Hemost, 39(7): 752-766, doi:…
[cited by applicant]
Freiburghaus, et al., “Tolerance Induction Using the Malmö Treatment Model 1982-1995”, Haemophilia, vol. 5, No. 1, pp. 32-39, Jan. 1999.
[cited by applicant]
Friend, P.J., et al., “Phase 1 study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection,” Transplantation 68(11):1632-1637, Lippincott Williams & Wilkins, Inc., United States (1999).
[cited by applicant]
Gayle, R.B., III., et al., “Identification of Regions in Interleukin-Iα Important for Activity,” The Journal of Biological Chemistry 268(29):22105-22111, The American Society for Biochemistry and Molecular Biology, Inc.…
[cited by applicant]
GenBank, “
[cited by applicant]
GenBank, “
[cited by applicant]
GenBank, “Variation in IgG1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies,
[cited by applicant]
George, et al., “Profile of Efraloctocog Alfa and its Potential in the Treatment of Hemophilia A”, Journal of Blood Medicine, vol. 6, pp. 131-141, Apr. 24, 2015.
[cited by applicant]
Geraghty, S., et al., “Practice patterns in haemophilia A therapy—global progress towards optimal care,” Haemophilia 12(1):75-81, Blackwell Publishing Ltd., England (2006).
[cited by applicant]
Gitschier, J., et al., “Characterization of the human factor VIII gene,” Nature 312(5992):326-330, Nature Publishing Group, England (1984).
[cited by applicant]
Gouw et al., (2013), “Factor VIII products and inhibitor development in severe hemophilia A”, N Engl J Med, 368(3): 231-239, doi: 10.1056/NEJMoa1208024.
[cited by applicant]
Graham, J.B., et al., “Canine Hemophilia: Observations on the Course, the Clotting Anomaly, and the Effect of Blood Transfusions,” The Journal of Experimental Medicine 90(2):97-111, The Rockefeller University Press, Uni…
[cited by applicant]
Green, D., “Factor VIII inhibitors: a 50-year perspective,” Haemophilia 17(6):831-838, Blackwell Publishing Ltd., England (Nov. 2011).
[cited by applicant]
Gringeri, (2007) “VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study”, Haemophilia, 13(Suppl 5): 73-77, doi:10.1111/j.1365-2516.2007.01579.x.
[cited by applicant]
Groomes et al., (2016) “Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein”, Pediatr Blood Cancer, 63(5): 922-924, doi:10.1002/pbc.25874.
[cited by applicant]
Grubb, J.H., et al., “Infused Fc-tagged β-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice,” Proceedings of the National Academy of Sciences USA 105(24)8375…
[cited by applicant]
Gupta et al., (2015) “Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance”, Sci Transl Med, 7(275): 275ra221, doi: 10.1126/scitranslmed.aaa1957.
[cited by applicant]
Hacker, M.R., et al., “Barriers to compliance with prophylaxis therapy in haemophilia,” Haemophilia 7(4):392-396, Blackwell Science, England (2001).
[cited by applicant]
Hay et al., (2012) “The principal results of the International Immune Tolerance Study: a randomized dose comparison”, Blood, 119(6): 1335-1344, doi:10.1182/blood-2011-08-369132.
[cited by applicant]
Hay, C.R.M., et al., “The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization,” British Journal of Haematology 133(6):591-605, Blackwell…
[cited by applicant]
Haya et al., (2001) “Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry”, Haemophilia, 7(2): 154-159.
[cited by applicant]
Healey, J.F., et al., “The cDNA and derived amino acid sequence of porcine factor VIII,” Blood 88(11):4209-4214, The American Society of Hematology, United States (1996).
[cited by applicant]
Herzog, R.W., et al., “Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector,” Nature Medicine 5(1):56-63, Nature Publishing Co., United St…
[cited by applicant]
Hoeben, R.C., et al., “Expression of Functional Factor VIII in Primary Human Skin Fibroblasts after Retrovirus-mediated Gene Transfer,” The Journal of Biological Chemistry 265(13):7318-7323, The American Society for Bio…
[cited by applicant]
Huang, C., “Receptor-Fc Fusion Therapeutics Traps, and MimetibodyTM Technology,” Current Opinion in Biotechnology 20(6):692-699, Current Biology, England (2009).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/021332, mailed Mar. 18, 2013.
[cited by applicant]
Ishiguro, “Immune Mechanisms Involved in the Development and Eradication of Anti-Factor VIII Alloantibodies in Hemophilia”, Japanese Journal of Clinical Immunology, vol. 34, Issue 6, pp. 476-484, 2011.
[cited by applicant]
Jimenez-Yuste et al., (2016) “Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/WF product: the long-term ITI study”, Haemophilia, 22(6):…
[cited by applicant]
Karpf, D.M., et al., “Preclinical pharmacokinetic (PK) evaluation of glycopegylated long acting RFVIII,” Hemophilia 16(Suppl. 4):40 Blackwell Publishing Ltd., England (2010).
[cited by applicant]
Kasper C.K., “Diagnosis and Management of Inhibitors to Factors VIII and IX: An Introductory Discussion for Physicians,” Treatment of Hemophilia 34:1-22, World Federation of Hemophilia, Canada (2004).
[cited by applicant]
Kau, et al., “Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes”, Current Opinion in Allergy and Clinical Immunology, vol. 14, No. 6, pp. 570-575, Dec. 2014.
[cited by applicant]
Kempton et al., (2014) “Toward optimal therapy for inhibitors in hemophilia”, Blood, 124(23): 3365-3372, doi: 10.1182/blood-2014-05-577643.
[cited by applicant]
Kempton, C.L., et al., “How we treat a hemophilia A patient with a factor VIII inhibitor,” Blood 113(1):11-17, The American Society of Hematology, United States (2009).
[cited by applicant]
Kreuz et al., (2016) “First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction…
[cited by applicant]
Kreuz, et al., “Immune Tolerance Therapy in Paediatric Haemophiliacs with Factor VIII Inhibitors: 14 Years Follow-up”, Haemophilia, vol. 1, No. 1, pp. 24-32, Jan. 1, 1995.
[cited by applicant]
Kreuz, W., et al., “When should prophylactic treatment in patients with haemophilia A and B start?—The German experience,” Haemophilia 4(4):413-417, Blackwell Science Ltd., England (1998).
[cited by applicant]
Krishnamoorthy et al., (2016) “Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice”, Cell Immunol, 301: 30-39, doi:10.1016/j.cellimm.2015.12.008.
[cited by applicant]
Kroner et al. (1999) “Comparison of the international immune tolerance registry and the North American immune tolerance registry”, Vox Sang, 77(Suppl 1): 33-37.
[cited by applicant]
Kurth et al., (2011) “The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience”, J Thromb Haemost, 9(11): 2229-2234, doi:10.1111/j.…
[cited by applicant]
Langner, K.D., et al., “Synthesis of Biologically Active Deletion Mutants of Human Factor VIII:C,” Behring Institute Mitteilungen 82:16-25, Behringwerke AG, Germany (1988).
[cited by applicant]
Lee, C.A., et al., “Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-Stage Clotting and Chromogenic Factor VIII Assay,” Thrombosis and Haemostasis 82(6): 1644-1647, Schattauer Verlag, Germany (1999).
[cited by applicant]
Lei, T.C., “Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins,” Blood 105(12):4865-4870, The American Society of Hematology…
[cited by applicant]
Lencer, W.I. and Blumberg, R.S., “A passionate kiss, then run: exocytosis and recycling of IgG by FcRn,” Trends in Cell Biology 15(1):5-9, Elsevier Science Publishers, England (2005).
[cited by applicant]
Lenting, P.J., et al., “Clearance mechanisms of von Willebrand factor and factor VIII,” Journal of Thrombosis and Haemostasis 5(7):1353-1360, Blackwell Publishing, England (2007).
[cited by applicant]
Liesner, R.J., et al., “The impact of prophylactic treatment on children with severe haemophilia,” British Journal of Haematology 92(4):973-978, Blackwell Publishing, England (1996).
[cited by applicant]
Lillicrap, D., “Improvements in factor concentrates,” Current Opinion in Hematology 17(5):393-397, Lippincott Williams & Wilkins, United States (2010).
[cited by applicant]
Ling, et al., “Classification of the Kinetics of Factor VIII Inhibitors in Haemophilia A: Plasma Dilution Studies Are More Discriminatory Than Time-Course Studies”, British Journal of Haematology, vol. 114, No. 4, pp. 8…
[cited by applicant]
Liu, T. Z., et al. “Recombinant FVIII Fc fusion protein is fully active in treating acute injury and demonstrates prolonged prophylactic efficacy in hemophilia A mice,” Journal of Thrombosis and Haemostasis 9(Supp.2):56…
[cited by applicant]
Liu, T., et al., “Evaluation of antibody responses to rFVIIIFc compared to Xyntha® and Advate® in hemophilia A mice,” Hemophilia 18(Suppl. 3):41, Blackwell Publishing Ltd., England (Jul. 9, 2012).
[cited by applicant]
Liu, T., et al., “Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in Hemophilia A Dogs,” 50th ASH Annual Meeting and Exposition Online Program and Ab…
[cited by applicant]
Livak, K.J. and Schmittgen T.D., “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method,” Methods 25(4):402-408, Academic Press, United States (2001).
[cited by applicant]
Ljung, R.C.R., “Prophylactic treatment in Sweden—overtreatment or optimal model?” Haemophilia 4(4):409-412, Blackwell Science Ltd., England (1998).
[cited by applicant]
Lofqvist, et al., “Haemophilia Prophylaxis In Young Patients ± a Long-Term Follow-Up”, Journal of Internal Medicine, vol. 241, pp. 395-400, 1997.
[cited by applicant]
Lollar, P. and Parker, E.T., “Structural Basis for the Decreased Procoagulant Activity of Human Factor VIII Compared to the Porcine Homolog,” Journal of Biological Chemistry 266(19):12481-12486, The American Society for…
[cited by applicant]
Lollar, P., et al., “Coagulant Properties of Hybrid Human/Porcine Factor VIII Molecules,” Journal of Biological Chemistry 267(33):23652-23657, The American Society for Biochemistry and Molecular Biology, Inc., United St…
[cited by applicant]
Lozier, J.N., et al., “The Chapel Hill Hemophilia A Dog Colony Exhibits a Factor VIII Gene Inversion,” Proceedings of the National Academy of Sciences USA 99(20): 12991-12996, The National Academy of Sciences, United St…
[cited by applicant]
Löfqvist, T., et al., “Haemophilia prophylaxis in young patients—a long term follow-up,” Journal of Internal Medicine 241(5):395-400, Blackwell Scientific Ltd., England (1997).
[cited by applicant]
Malec et al., (2015) “Immune Tolerance Induction Using rFVIIIFc (Eloctate)”, Blood, 126(23): 3531-3531.
[cited by applicant]
Malec et al., (2016) “Extended half-life factor VIII for immune tolerance induction in haemophilia”, Haemophilia, 22(6): e552-e554, doi: 10.1111/hae.13064.
[cited by applicant]
Manco-Johnson, M., et al., “Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia,” New England Journal of Medicine 357(6):535-544, Massachusetts Medical Society, United States (2…
[cited by applicant]
Manucci, P.M. and Tuddenham, E.G.D, “The hemophilias—from royal genes to gene therapy,” The New England Journal of Medicine 344(23):1773-1779, Massachusetts Medical Society, United States (2001).
[cited by applicant]
Mariani et al., (1994) “Immune tolerance in hemophilia-principal results from the International Registry—Report of the factor VIII and IX Subcommittee”, Thromb Haemost, 72(1): 155-158.
[cited by applicant]
Mariani et al., “Immune tolerance induction in hemophilia A: a review”, Semin Thromb Hemost., Feb. 2003, 29(1): 69-76.
[cited by applicant]
McCue, J.T., et al., “Applicants of a Novel Affinity Adsorbent for the Capture and Purification of Recombinant Factor VIII Compounds,” Journal of Chromatography A 1216(45):7824-7830, Elsevier, Netherlands (2009).
[cited by applicant]
Mei, B., et al., “Rational design of fully active, long lasting PEGylated factor VIII for hemophilia A Treatment,” Blood 116(2):270-279, The American Society of Hematology, United States (2010).
[cited by applicant]
Meslier, Y., et al., “Induction of Tolerance to Therapeutic FVIII by Materno-Fetal Transfer in a Hemophilia A mouse model,” European Journal Immunology 2009: Tuesday, Poster Sessions, abstract PD11/26, p. S536, Wiley-VC…
[cited by applicant]
Metzner, H.J., et al., “Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis,” Haemophilia 4(Suppl. 3):25-32, Blackwell Science Ltd., Engl…
[cited by applicant]
Metzner, H.J., et al., “Genetic fusion to albumin improves the pharmacokinetic properties of factor IX,” Journal of Thrombosis and Haemostasis 102(4):634-644, Stuttgart, Schattauer, Germany (2009).
[cited by applicant]
Meulien, P., et al., “A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII,” Protein Engineering 2(4):301-306, IRL Press Ltd., England (1988).
[cited by applicant]
Mikaelsson, M. and Oswaldsson, U., “Assaying the Circulating Factor VIII Activity in Hemophilia A Patients Treated with Recombinant Factor VIII Products,” Seminars in Thrombosis and Hemostasis 28(3):257-264, Thieme, Uni…
[cited by applicant]
Molho, P., et al., “Epidemiological survey of the orthopaedic status of severe hemophilia A and B patients in France,” Haemophilia 6(1):23-32, Blackwell Science Ltd., England (2000).
[cited by applicant]
Morfini, M., “Pharmacokinetics of factor VIII and factor IX,” Hemophilia 9(Suppl. 1):94-100, Blackwell Publishing Ltd., England (2003).
[cited by applicant]
Møss, J., et al., “Safety and pharmacokinetic of a glycoPEGylated recombinant activated factor VIII derivative: a randomized first human dose trial in healthy subjects,” Journal of Thrombosis and Haemostasis 9(7):1368-1…
[cited by applicant]
Nakar et al., (2015) “Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres”, Haemophilia, 2…
[cited by applicant]
Negrier, C., et al., “Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B,” Blood 118(10):2695-2701, The American Society of Hematology, …
[cited by applicant]
Ngo, J.C.K., et al., “Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor Villa complex,” Structure 16(4):597-606, Cell Press, United States (2008).
[cited by applicant]
Nilsson, I.M., et al., “Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B,” Journal of Internal Medicine 232(1):25-32, Blackwell Scientific Publications, England (1992).
[cited by applicant]
Noble, et al., “IL-12 and IL-4 Activate a CD39-Dependent Intrinsic Peripheral Tolerance Mechanism in CD+ T Cells”, European Journal of Immunology, vol. 46, No. 6, 11 Pages, Jun. 2016.
[cited by applicant]
Oganesyan, V., et al., “Structural characterization of a human Fc fragment engineered for extended serum half-life,” Molecular Immunology 46(8-9):1750-1755, Pergamon Press, England (2009).
[cited by applicant]
Oldenburg et al., (2006) “Genetic risk factors for inhibitors to factors VIII and IX”, Haemophilia, 12(Suppl 6): 15-22, doi:10.1111/j.1365-2516.2006.01361.x.
[cited by applicant]
Oldenburg et al., (2014) “Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate”, Haemophilia, 20(1): 83-91, doi:1…
[cited by applicant]
Pan, J., et al., “Enhanced Efficacy of Recombinant FVIII in Noncovalent Complex with PEGylated Liposome in Hemophilia A Mice,” Blood 114(13):2802-2811, The American Society of Hematology, United States (2009).
[cited by applicant]
Pavlova, A., et al., “Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemop…
[cited by applicant]
Persson, E., et al., “Rational design of coagulation factor VIIa variant with substantially increased intrinsic activity,” Proceedings of the National Academy of Sciences USA 98(24):13583-13588, The National Academy of …
[cited by applicant]
Persson, E., et al., “Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity,” The Journal of Biological Chemistry 276(31):29195- 29199, The American Society for Biochemistry an…
[cited by applicant]
Peters, R.T., et al., “Biochemical and Functional Characterization of a Recombinant Monomeric Factor VIII-Fc Fusion Protein,” Journal of Thrombosis and Haemostasis 11(1):132-141, Blackwell Publishing, England (Published…
[cited by applicant]
Peters, R.T., et al., “Prolonged Activity of Factor IX as a Monomeric Fc Fusion Protein,” Blood 115(10): 2057-2064, The American Society of Hematology, United States (Mar. 2010; Prepub. Online Jan. 2010).
[cited by applicant]
Petrini, P., et al., “Prophylaxis with factor concentrates in preventing hemophilic arthropathy,” The American Journal of Pediatric Hematology/Oncology 13(3):280-287, Raven Press, United States, (1991).
[cited by applicant]
Petrovan, R.J. and Ruf, W., “Residue Met156 Contributes to the Labile Enzyme Conformation of Coagulation Factor VIIa,” The Journal of Biological Chemistry 276(9):6616-6620, The American Society for Biochemistry and Mole…
[cited by applicant]
Peyvandi, F., et al., “Genetic diagnosis of haemophilia and other inherited bleeding disorders,” Haemophilia 12(Suppl. 3):82-89, Blackwell Publishing Ltd., England (2006).
[cited by applicant]
Powell, J.S., et al., “Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients,” Blood 119(13):3031-3037, The American Society of Hematology, United States (Mar. 29, 2012).
[cited by applicant]
Qadura, M., et al., “Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells,” Journal of Thrombosis and Haemostasis 6(12):2095-2104, Blackwell P…
[cited by applicant]
Report of Expert Meeting on FVIII Products and Inhibitor Development, European Medicines Agency, London, England, Feb. 28, 2006-Mar. 2, 2006.
[cited by applicant]
Risebrough, N., et al., “Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A,” Haemophilia 14(4):743-752, Blackwell Publishing Lt…
[cited by applicant]
Roberts, S.A., et al., “Engineering factor Viii for Hemophilia Gene Therapy,” Genetic Syndrome Gene Therapy S1: 1-7, OMICS, India (2011).
[cited by applicant]
Rocino, et al., “Successful Immune Tolerance Treatment with Monoclonal or Recombinant Factor VIII Concentrates in High Responding Inhibitor Patients”, Vox Sanguinis, vol. 77, Supplement 1, pp. 65-69, Sep. 2001.
[cited by applicant]
Rodriguez-Merchan, E.C., “Management of Musculoskeletal Complications of Hemophilia,” Seminars in Thrombosis and Hemostasis 25(1):87-95, Thieme, United States (2003).
[cited by applicant]
Rojas, et al., “IL-10: A Multifunctional Cytokine in Viral Infections”, Review Article, Journal of Immunology Research, 15 Pages, Feb. 20, 2017.
[cited by applicant]
Ron, D., et al., “Expression of Biologically Active Recombinant Keratinocyte Growth Factor: Structure/function analysis of amino-terminal truncation mutants,” The Journal of Biological Chemistry 268(4):2984-2988, Americ…
[cited by applicant]
Roopenian, D.C., and Akilesh, S., “FcRn: the Neonatal Fc Receptor Comes of Age,” Nature Reviews Immunology 7(9):715-725, Nature Publishing Group, England (2007).
[cited by applicant]
Rosén, S., “Assay of Factor VIII:C with a Chromogenic Substrate,” New Frontiers in Hemophilia Research, the XVth World Federation of Hemophilia Congress Stockholm, Sweden, Jun. 27-Jul. 1, 1983, published in Scandinavian…
[cited by applicant]
Routledge, E.G., et al., “The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody,” Transplantation 60(8):847-853, Williams & Wilkins, United States (1995).
[cited by applicant]
Röstin, J., et al., “B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monotherapy Polyethylene Glycol,” Bioconjugate Chemistry 11(3):387- 396, American Chemical Society, United States (2000).
[cited by applicant]
Sakurai, et al., “Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder”, Journal of Immunology Research, vol. 2014, Article ID 320674, 10 Pages, Mar. 24, 2014.
[cited by applicant]
Salas, J., et al., “Enhanced pharmacokinetics of factor VIIA as a monomeric FC Fusion,” Journal of Thrombosis and Haemostasis 9(Suppl. 2):268, Blackwell Publishing, England (Jul. 2011).
[cited by applicant]
Sarver, N., et al., “Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector,” DNA 6(6):553-564, Mary Ann Liebert, Inc., United States (1987).
[cited by applicant]
Scalone et al., (2006) “Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors”, Haemophilia, 12(2): 154-162, doi:10.1111/j.1365-2516.2006.01204.x.
[cited by applicant]
Schmidt, S.R., “Fusion proteins as biopharmaceuticals—Applications and challenges,” Current Opinion in Drug Discovery & Development 12(2):284-295, Thomson Reuters, England (2009).
[cited by applicant]
Shen, B.W., et al., “The tertiary structure and domain organization of coagulation factor VIII,” Blood 111(3):1240-1247, The American Society of Hematology, United States (2007).
[cited by applicant]
Shields, R.L., et al., High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FCyRII, FCγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR* The Journal of Biological Chemistry 27…
[cited by applicant]
Sichler, K., et al., “Physiological fl Xa activation involves a cooperative conformational rearrangement of the 99-loop,” The Journal of Biological Chemistry 278(6):4121-4126, The American Society for Biochemistry and M…
[cited by applicant]
Simioni, P., et al., “X-linked thrombophilia with a mutant factor IX (factor IX Padua),” The New England Journal of Medicine 361(17):1671-1675, Massachusetts Medical Society, United States (2009).
[cited by applicant]
Simister, “Placental Transport of Immunoglobulin G”, Vaccine, vol. 21, No. 24, pp. 3365-3369, Jul. 28, 2003.
[cited by applicant]
Simister, N.E., “Placental transport of immunoglobulin G,” Vaccine 21(24):3365-3369, Elsevier Science, Netherlands (2003).
[cited by applicant]
Smith, N.L., et al., “Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consor…
[cited by applicant]
Soejima, K., et al., “Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property,” The Journal of Biological Chemistry 276(20):17229-17235, The American Society …
[cited by applicant]
Soejima, K., et al., “The 99 and 170 loop-modifier factor VIIa mutants show enhanced catalytic activity without tissue factor,” The Journal of Biological Chemistry 277(50):49027-49035, The American Society for Biochemis…
[cited by applicant]
Spitzer, S.G., et al., “Replacement of isoleucine-397 threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysi…
[cited by applicant]
Srivastava et al., (Jan. 2013) “Guidelines for the management of hemophilia”, Haemophilia, 19(1): e1-47, doi:10.1111/j.1365-2516.2012.02909.x.
[cited by applicant]
Story, C.M., et al., “A Major Histocompatibility Complex Class I-Like Fc Receptor Cloned from Human Placenta: Possible Role in Transfer of Immunoglobulin G from Mother to Fetus,” The Journal of Experimental Medicine 180…
[cited by applicant]
Stroobants, A.K., et al., “Differences between one stage clotting and chromogenic factor VIII assay results,” Journal of Thrombosis and Haemostasis 9(Suppl 2):381 (Abstract P-TU-230), Blackwell Publishing, England (Jul.…
[cited by applicant]
Strürzebecher, J., “Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols,” FEBS Letters 412(2):295-300, Federation of European Biochemical Societies, Netherlands (1997).
[cited by applicant]
Supplementary European Search Report received for European Patent Application No. 13735995.6, mailed on Jul. 27, 2015.
[cited by applicant]
Tagariello et al., (2013) “High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance”, J Hematol Oncol, 6: 63, do…
[cited by applicant]
Toole, J.J., et al., “A large region (˜95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity,” Proceedings of the National Academy of Sciences USA 83(16):5939-5942, National Academy of Sciences,…
[cited by applicant]
Toole, J.J., et al., “Molecular cloning of a cDNA encoding human antihaemophilic factor,” Nature 312(5992):342-347, Nature Publishing Group, England (1984).
[cited by applicant]
Vaccaro, C., et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nature Biotechnology 23(10):1283-1288, Nature America Publishing, United States (2005).
[cited by applicant]
Valentino et al., (2015) “US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors”, Haemophilia, 21(5): 559-567, doi:10.1111/hae.12730.
[cited by applicant]
Van Den Berg, H.M., et al., “Comparing outcomes of different treatment regimens for severe haemophilia,” Haemophilia 9(1 Suppl):27-31, Blackwell Science, United States (2003).
[cited by applicant]
Van Den Berg, H.M., et al., “Issues surrounding therapeutic choices for hemophilia patients,” Haematologica 89(6):645-650, Ferrata Storti Foundation, Italy (2004).
[cited by applicant]
Van Rooijen, et al., “Liposomes for Specific Depletion of Macrophages from Organs and Tissues”, Methods of Molecular Biology, vol. 605, pp. 189-203, 2010.
[cited by applicant]
Van Rooijen, N. et al., “Liposomes for specific depletion of macrophages from organs and tissues,” Methods in Molecular Biology 605:189-203, Humana Press, United States (2010).
[cited by applicant]
Van Schooten, C.J., et al., “Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo,” Blood 112(5):1704-1712, The American Society of Hematology, United States (2008).
[cited by applicant]
Van Schooten, et al., “Macrophages Contribute to the Cellular Uptake of Von Willebrand Factor and Factor VIII in Vivo”, Blood, vol. 112, No. 5, pp. 1704-1712, Sep. 1, 2008.
[cited by applicant]
Vasanthi, et al., “Role of Tumor Necrosis Factor-Alpha in Rheumatoid Arthritis: a Review”, APLAR Journal of Rheumatology, vol. 10, No. 4, pp. 270-274, Dec. 2007.
[cited by applicant]
Vehar, G.A., et al., “Structure of human factor VIII,” Nature 312(5992):337-342, Nature Publishing Group. England (1984).
[cited by applicant]
Vysotchin, A., et al., “Domain structure and domain-domain interactions in human coagulation factor IX,” The Journal of Biological Chemistry 268(12):8436-8446, The American Society for Biochemistry and Molecular Biology…
[cited by applicant]
Wakabayashi, H., et al., “Residues 110-126 in the A1 Domain of Factor VIII Contain a Ca2+ Binding Site Required for Cofactor Activity,” The Journal of Biological Chemistry 279(13):12677-12684, The American Society for B…
[cited by applicant]
Ward, E.S, and Ghetie, V., “The effector functions of immunoglobulins: implications for therapy,” Therapeutic Immunology 2(2):77-94, Blackwell Science Ltd., England (1995).
[cited by applicant]
Weimer, T., et al., “Prolonged in-vivo half-life of factor VIIa by fusion to albumin,” Thrombosis and Haemostasis 99(4):659-667, Stuttgart, Schattauer, Germany (2008).
[cited by applicant]
Whelan et al., (2013) “Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients”, Blood, 121(6): 1039-1048, doi: 10.1182/blood-2012-07-4…
[cited by applicant]
White, G.C., 2nd., et al., “A multicenter study of recombinant factor VIII (recombinate TM) in previously treated patients with hemophilia A. The Recombinate previously treated patient study group,” Thrombosis and Haemo…
[cited by applicant]
Wood., W.I., et al., “Expression of active human factor VIII from recombinant DNA clones,” Nature 312(5992):330-337, Nature Publishing Group, England (1984).
[cited by applicant]
Yoshida, M., et al., Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells, Immunity 20(6):769-783, Cell Press, United States (2004).
[cited by applicant]
Zögg, T. and Brandstetter, H., “Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa,” Structure 17(12):1669-1678, Cell Press, United States (2009).
[cited by applicant]
U.S. Appl. No. 14/371,931 2014/0370035 U.S. Pat. No. 10,221,455, filed Jul. 11, 2014 Dec. 18, 2014 Mar. 5, 2019, Haiyan Jiang, Methods of Reducing Immunogenicity Against Factor VIII in Individuals Undergoing Factor VIII…
[cited by applicant]
U.S. Appl. No. 16/246,225 2019/0241960 U.S. Pat. No. 11,286,528, filed Jan. 11, 2019 Aug. 8, 2019 Mar. 29, 2022, Haiyan Jiang, Methods of Reducing Immunogenicity Against Factor VIII in Individuals Undergoing Factor VIII…
[cited by applicant]
U.S. Appl. No. 17/681,435 2023/0002828, filed Feb. 25, 2022 Jan. 5, 2023, Haiyan Jiang, Methods of Reducing Immunogenicity Against Factor VIII in Individuals Undergoing Factor VIII Therapy.
[cited by applicant]